MDUFA IV (And More) Is Law: Trump Signs A Health-Care Bill

18 Aug 2017
Analysis

Executive Summary

President Trump's eleventh-hour signature on the FDA Reauthorization Act puts into play about $1bn in device user-fee collections from industry through FY 2022, new US FDA performance goals and a range of device process enhancements and reforms supported by industry.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

Subjects
Policy
Legislation
Regions
North America

United States

Industries
Medical Device

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Policy Legislation United States

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT105334

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT105334

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

MDUFA IV (And More) Is Law: Trump Signs A Health-Care Bill

Analysis

Executive Summary

Related Content

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert